anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Autophagy is a degradation process that is evolutionarily conserved and is essential in maintaining cellular and physiological homeostasis through lysosomal removal and elimination of damaged peptides, proteins and cellular organelles. The dysregulation of autophagy is implicated in various diseases and disorders, including cancers, infection-related, and metabolic syndrome-related diseases. Propolis has been demonstrated in various studies including many human clinical trials to have antimicrobial, antioxidant, anti-inflammatory, immune-modulator, neuro-protective, and anti-cancer. Nevertheless, the autophagy modulation properties of propolis have not been extensively studied and explored. The role of propolis and its bioactive compounds in modulating cellular autophagy is possibly due to their dual role in redox balance and inflammation. The present review attempts to discuss the activities of propolis as an autophagy modulator in biological models in relation to various diseases/disorders which has implications in the development of propolis-based nutraceuticals, functional foods, and complementary therapies.
Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. Current HAI therapy regimens often alternate FUDR with systemic chemotherapy. This study will examine the addition of a one hour isolated hepatic perfusion with 5-FU and Oxaliplatin prior to this standard treatment. Subjects will be given the consent form to review and after sufficient time to review the information, interested subjects will have the opportunity to ask questions of the investigators. Subjects interested in enrolling in the trial will then sign informed consent and clinical data will be collected from their chart to ensure that they meet eligibility requirements. The study will consist of a one hour isolated liver perfusion that will be performed at the time of the laparotomy to place the HAI therapy pump. Following surgery subjects will be monitored in the ICU for 24-48 hours and potentially in the hospital for an additional 5-7 days. Subjects will be free to start standard HAI therapy regimens four to six weeks following surgery. The duration of treatment, dose of HAI therapy and the decision to combine HAI with systemic chemotherapy will be at the discretion of the treating physician.
The invention belongs to the field of medicines, and concretely relates to an urticaria treatment medicine. The medicine comprises 30g of Radix Astragali, 30g of Fructus Kochiae, 20g of Rhizoma Anemarrhenae, 15g of gypsum, 15g of coix seed, 15g of Rhizoma Atractylodis Macrocephalae, 15g of dried orange peel, 10g of branch, 20g of Rhizoma Alismatis and 15g of licorice root. A preparation method of the medicine comprises the following steps: mixing the above medicines, rapidly flushing, immersing for 2h, boiling for 30min three times, filtering, concentrating the obtained filtrate, and processing through a routine traditional Chinese medicinal preparation method to prepare particles. The medicine is taken according to a medicine/raw medicines ratio of 5g/kg once every day. The medicine is used for treating urticaria, and has the efficacies of spleen invigorating, dampness disinhibiting, right supporting and evil dispelling. The medicine is used to clinically diagnose and treat 15 patients, 15 patients are cured, and a result of one year follow-up shows that no urticaria recurs.
Apparatus, systems, and methods for imaging protocol management are disclosed and described. An example imaging protocol manager includes an orchestrator, a baseliner, and a protocol application. The example orchestrator is to trigger a pull of a first imaging protocol. The example baseliner is configured to at least: process the first imaging protocol; and evaluate the first imaging protocol in comparison to a second imaging protocol from a protocol library to identify the first imaging protocol as at least one of a matching protocol, a new protocol, or a deviation with respect to the second imaging protocol, the deviation to be identified when the first imaging protocol is a partial match to the second imaging protocol. When the deviation is identified, the example baseliner is configured to remediate the deviation. When the first imaging protocol is identified as new, the example baseliner is to trigger storage of the first imaging protocol.
This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
Angiotensin (Ang)-(1-7) is a cardioprotective peptide of the renin-angiotensin system. Prepuberty has been considered as a later susceptible window of development, and stressful factors in this life phase can induce chronic diseases in adulthood. We aimed to investigate whether the treatment with Ang-(1-7) during the prepuberty could attenuate the development of hypertension and cardiac injury in adult spontaneously hypertensive rats (SHRs). SHRs were treated with Ang-(1-7) (24 μg/kg/h) from age 4 to 7 weeks. Systolic blood pressure was measured by tail-cuff plethysmography up to 17th week. Thereafter, echocardiography was performed, and the rats were euthanized for the collection of tissues and blood. Ang-(1-7) did not change the systolic blood pressure but reduced the septal and posterior wall thickness, and cardiomyocyte hypertrophy and fibrosis in SHR. In addition, Ang-(1-7) reduced the gene expression of atrial natriuretic peptide and brain natriuretic peptide, increased the metalloproteinase 9 expression, and reduced the extracellular signal-regulated kinases 1/2 phosphorylation. Ang-(1-7) also prevented the reduction of Mas receptor but did not change the protein expression of angiotensin-converting enzyme, angiotensin-converting enzyme 2, AT1, and AT2. The treatment with Ang-(1-7) decreased the malondialdehyde (MDA) levels and increased superoxide dismutase-1 and catalase activities and protein expression of catalase. Our findings demonstrate that the treatment of SHR with Ang-(1-7) for 3 weeks early in life promotes beneficial effects in the heart later in life, even without altering blood pressure, through mechanisms involving the reduction of oxidative stress and ERK1/2 phosphorylation. In addition, this study supports the prepuberty as an important programming window.
INTRODUCTION: Atrophy of the nucleus basalis of Meynert (NBM) is an early indicator of Alzheimer's disease (AD). However, reduced integrity of the NBM white matter tracts may be more relevant for cognitive impairment and progression to dementia than NBM volume. Research is needed to compare differences in NBM volume and integrity of the lateral and medial NBM tracts across early and later stages of AD progression.
METHODS: 187 participants were included in this study who were either healthy controls (HC; n = 50) or had early mild cognitive impairment (EMCI; n = 50), late MCI (LMCI; n = 37), or AD (n = 50). NBM volume was calculated using voxel-based morphometry and mean diffusivity (MD) of the lateral and medial NBM tracts were extracted using probabilistic tractography. Between group differences in NBM volume and tract MD were compared using linear mixed models controlling for age, sex, and either total intracranial volume or MD of a control mask, respectively. Associations between NBM volume and tract MD with executive function, memory, language, and visuospatial function were also analysed.
RESULTS: NBM volume was smallest in AD followed by LMCI (p < 0.0001), with no difference between EMCI and HC. AD had highest MD for both tracts compared to all other groups (p < 0.01). Both MCI groups had higher lateral tract MD compared to HC (p < 0.05). Medial tract MD was higher in LMCI (p = 0.008), but not EMCI (p = 0.09) compared to HC. Higher lateral tract MD was associated with executive function (p = 0.001) and language (p = 0.02).
DISCUSSION: Integrity of the lateral NBM tract is most sensitive to the earliest stages of AD and should be considered an important therapeutic target for early detection and intervention.
The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
<P>PROBLEM TO BE SOLVED: To obtain a crude medicine for feed addition specialized for every classification of baby pigs, male pigs and female pigs.  <P>SOLUTION: The crude medicine for feed addition for baby pigs comprises dried leaves of Lycium chinense Miller, malt and dried leaves of Eriobotrya japonica Lindley as essential components. The crude medicine for feed addition for male pigs comprises dried root of Panax ginseng, dried leaves of Lycium chinense Miller, steamed rhizome of Polygonatum falcatum or Polygonatumsibiricum Redoute and dried rhizome of Dioscorea japonica Thunberg or Dioscorea batatas Decaisne as essential components. The crude medicine for feed addition for female pigs comprises dried root of Panax ginseng, dried root of Taraxacum officinale Weber, dried fruit of Zizyphus jujuba Miller var. inermis Rehder, dried rhizome of Dioscorea japonica Thunberg or Dioscorea batatas Decaisne and dried terrestrial part of Stellaria neglecta Weihe as essential components.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
A vehicle for an active pharmaceutical ingredient is disclosed, wherein the vehicle comprises a viscosity enhancing component, a wetting agent, a pH buffer and a polyol. A pharmaceutical composition is also disclosed, comprising the vehicle and an active pharmaceutical ingredient, such as omeprazole. Furthermore, a method of manufacturing the same comprises the steps of mixing a viscosity enhancing component with a wetting agent to form a mixture and adding a pH buffer and a polyol to the mixture to form a vehicle. The vehicle can be mixed with an active pharmaceutical ingredient. The viscosity enhancing agent may be an alkali metal carboxymethyl cellulose, preferably sodium carboxymethyl cellulose. The wetting agent may be sorbitol, glycerine, a polysorbate or preferably propylene glycol. The pH buffer may be calcium bicarbonate, magnesium bicarbonate, calcium carbonate or preferably sodium bicarbonate. The polyol may be a sugar alcohol. Suitable sugar alcohols include sorbitol, mannitol, xylitol or preferably maltitol. The composition has an improved shelf-life.
The present invention relates to a quick-acting Xingnao pill which is refreshing brain and inducing resuscitation Chinese medicine used for treating encephalopathy and improving the functions of encephalon. The pill is prepared from antelope horn powder, cow-bezoar, borneol, twotoothed achyranthes root, wolfberry bark, curcuma root, figwort root, corydalis, acorus calamus, sharpleaf galangal fruit, etc. The materials are crushed and extracted to prepare soft pills. The present invention has the functions of treating closed pathological symptoms, inducing resuscitation, refreshing the brain and returning the spirit. The present invention is used for treating closed pathological symptoms, faint pathological symptoms and qi desertion pathological symptoms because of encephalon consumption and failure and lose control of nerves of the brains, is especially suitable for high heat due to heat encephalon, nerves desertion, faint, brain dysphoria, crankiness and wild talks, limb hemiparalysis, chest distress and breathe hard, brain pain and word dullness, manic-depressive psychosis and limb unfavorable activity, the two of which are because of congenital and acquired poor development of children's encephalons. Consequently, the present invention discloses medicine for treating encephalopathy and encephalon disease.
An industrial production method of teprenone and its application. The invention belongs to the field of teprenone synthesis. The invention aims to solve the technical problems that the existing teprenone synthesis method is long in route, multiple in side reaction and needs to use special reagents. The method comprises the following steps: firstly, reacting farnesene with acetoacetate under the action of a catalyst to obtain farnesene ketoester, then decarboxylating to generate farnesene acetone, and then carrying out reduction reaction, halogenation reaction and Wittig reaction to obtain teprenone. The method avoids the defects of the prior art, has few conversion steps of a synthetic route, has high yield and high purity of the prepared teprenone, and is suitable for industrial production. The teprenone of the present invention is used as medicine for treating gastropathy.
New recombinant oncolytic viral vectors have been constructed based on a known herpes simplex virus-1 with a single 34.5 gene and a synctial mutation (called OncSyn (OS) virus), which was designed to be more immunogenic than the parental OS virus largely due to deletion of the viral gene viral host shutoff (vhs) gene (the “OSV” virus). In another embodiment, the OSV virus was constructed to constitutively express 15-PGDH (the “OSVP” virus), the principal enzyme responsible for degradation of PGE2. OSVP was shown to decrease both breast tumors and prostate cancer tumors in mice models. In addition, OSVP was shown to trigger substantial inflammatory cytokine production and pro mote anti-tumor immune responsiveness. These altered viruses, OSV and OSVP, can be used to treat various cancers including breast, prostate, liver, colon, and other tissues. Other exogenous genes can be added to either OSV or OSVP to improve the therapeutic response.
If the SLN can be accurately identified and the detection of metastatic lymph nodes in women with early stage high risk endometrial cancer can be improved then the majority of women could avoid a complete systematic pelvic lymphadenectomy. Pelvic lymphadenectomy is associated with many intraoperative and postoperative complications such as hemorrhage, lymphocyst formation, nerve injury and chronic lower extremity lymphedema. If less invasive techniques to assess regional lymph node involvement, such as SLN mapping, replaced routine pelvic lymphadenectomy the complications associated with more extensive pelvic surgery could be avoided.

This will be a prospective cohort study. The population to be studied will be patients with newly diagnosed early stage high risk endometrial cancer who will undergo primary surgical intervention that includes hysterectomy and bilateral pelvic and inframesenteric para-aortic lymphadenectomy via laparotomy, laparoscopy or robotic-assisted. Patients will be taken to the operating room for their planned procedure. After initiation of general anesthesia, fluorescent dye (indocyanine green, ICG) will be injected into the patient's cervix. The dye will be visualized by excitation with an infrared light (an attachment on the Novadaq Pinpoint system for laparoscopy). The surgery will proceed and all lymph nodes that are "green" will be removed surgically and their anatomic location and laterality documented. These "green" sentinel nodes will be assessed by a study pathologist by frozen section and the result read out intraoperatively. The hysterectomy and complete lymphadenectomy will then be performed. The SLN status will be compared to the status of the other nodes removed at complete lymphadenectomy. All data on these patients will be prospectively collected.
Cataracts are primarily caused by aging or gene mutations and are the leading cause of blindness globally. As the older population increases, the number of patients with a cataract is expected to grow rapidly. At present, cataract surgery to replace the lens with an artificial intraocular lens is the principal treatment method. However, surgery has several drawbacks, including economic burdens and complications such as inflammation, xerophthalmia, macular edema and posterior capsular opacification. Thus, developing an effective non‑surgical treatment strategy is beneficial to both patients and public health. Mechanistically, cataract formation may be due to various reasons but is primarily initiated and promoted by oxidative stress and is closely associated with crystallin aggregation. In the present review, the current research progress on anti‑cataract drugs, including antioxidants and protein aggregation inhibitors is examined. It summarizes strategies for preventing and treating cataract through cell apoptosis and protein aggregation inhibition while discussing their limitations and further prospects.
In this work, a promising treatment strategy for triggering robust antitumor immune responses in transarterial chemoembolization of hepatocellular carcinoma (HCC) is presented. The zeolitic imidazolate framework nanoparticles loaded with hypoxia-activated prodrug tirapazamine and immune adjuvant resiquimod facilitated in situ generation of nanovaccine via a facile approach. The nanovaccine can strengthen the ability of killing the liver cancer cells under hypoxic environment, while was capable of improving immunogenic tumor microenvironment and triggering strong antitumor immune responses by increasing the primary and distant intratumoral infiltration of immune cells such as cytotoxic T cells. Moreover, a porous microcarrier, approved by FDA as pharmaceutical excipient, was designed to achieve safe and effective delivery of the nanovaccine via transarterial therapy in rabbit orthotopic VX2 liver cancer model. The microcarrier exhibited the characteristics of excellent drug loading and occlusion of peripheral artery. The collaborative delivery of the microcarrier and nanovaccine demonstrated an exciting inhibitory effect on solid tumors and tumor metastases, which provided a great potential as novel combination therapy for HCC interventional therapy.
PURPOSE:To obtain a galenical drug type antibacterial agent against staphylococcus, especially against MRSA, containing an extract of the cap part of fruit body of Fomes japonicus. CONSTITUTION:This galenical drug type antibacterial agent against staphylococcus contains an extract of the cap part of fruit body of Fomes japonicus which is especially completely ripened and has a great number of grown spores. The extract, for example, is obtained by grinding the cap part of fruit body of Fomes japonicus, extracting the ground material with hot water and spray- drying the extracted solution by a conventional procedure. The extracted solution is pharmaceutically manufactured into an external preparation such as solution or ointment or internal preparation such as powder, capsule or solution. In the case of the external preparation, the preparation contains 5-15wt.% of the extract and in the case of the internal preparation, a dose is 5-35mg/kg and administered twice or three times daily. The antibacterial agent shows an excellent inhibitory effect on growth of staphylococcus and is effective for treating and preventing inflammations, food poisoning, etc. The antibacterial agent shows excellent inhibitory effect on growth of MRSA and is effective for preventing and treating infection in hospital caused by the bacteria.
Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with then complete a 24-week intervention aimed to improve education about inflammatory bowel disease and scheduled nurse phone call reminders.
Participants will receive non-ablative dual-wavelength diode laser therapy for Genitourinary Syndrome of Menopause (GSM). The intervention includes three monthly sessions using the Leonardo® Diode laser (Biolitec®) with wavelengths of 980 nm and 1470 nm. Each session lasts about 20 minutes and involves 8 pulses per centimeter along the vaginal canal. Local lidocaine gel is used as an anesthetic. Evaluations occur at baseline, 3 months, and 6 months post-treatment.
BACKGROUND: Pretarsal atrophy is not uncommonly found in patients who have undergone a transcutaneous or transconjunctival lower blepharoplasty because of intraoperative denervation of the pretarsal orbicularis oculi. The motor-supplying concept to the lower eyelid was recently updated; however, there have not yet been any guidelines to preserve motor nerves in lower blepharoplasty incisions based on the refined knowledge.
METHODS: Forty-six fresh cadaveric hemifaces were examined to find a safe zone for a lower blepharoplasty muscle incision and a danger zone for an infraorbital incision in the transblepharoplasty midface approach. In addition, practical anatomy about the pretarsal motor supply was also investigated in detail.
RESULTS: The medial, lateral, superior, and inferior borders of the safe zone for a lower blepharoplasty muscle incision were 9.4 mm from the medial canthus line, 3 mm from the lateral canthal crease, and 6.0 and 6.5 mm from the eyelid margin, respectively. The danger zone for an infraorbital incision ranged from 9.4 mm medial to the midpupillary line to 9.7 mm lateral to the midpupillary line. The motor nerve in the danger zone abutted the distal roof of the preseptal pocket, making it vulnerable to electrocautery heat. Motor nerve distribution of the lower pretarsal orbicularis oculi was fully identified.
CONCLUSIONS: There is a safe zone for the lower blepharoplasty muscle incision which, if adhered to, will preserve the pretarsal motor supply and prevent muscle atrophy. There is an infraorbital danger zone, where surgeons should pay special attention to avoid electrocautery heat injury.
The pre-ovulatory surges of GnRH and LH are activated by increased concentrations of circulating estradiol, but ovulation is blocked when progesterone concentrations are elevated, due to a central inhibition of the GnRH surge. Although traditionally GnRH has been traditionally considered the drug of choice to control endogenous LH in controlled ovarian stimulation (COS) cycles, recently, micronized progesterone has been shown to be an effective oral alternative for preventing premature LH surges during COS in women undergoing IVF/ICSI treatments, with excellent results, whereas their safety during pregnancy is well-established. This novel protocol, has several advantages (good tolerance, user convenience, and cost reduction), that are very attractive when it comes to establishing a convenient user regimen in combination with a ''freeze all'' strategy. However, the comparative efficacy of this novel protocol with the more universal use of GnRH-antagonist protocol for the treatment of IVF patients in terms of embryo ploidy has never been evaluated up to date. The current study aims, for the first time, to examine whether the number of euploid embryos following ovarian stimulation with micronized progesterone is equivalent as compared with the number of embryos after ovarian stimulation with the use of a GnRH antagonist in patients undergoing ovarian stimulation for IVF/ICSI.

If efficacy would prove to be similar, with no impact on the chromosomal constitution of embryos, there will be obvious advantages for the preferential use of micronized progesterone over the antagonist protocol: oral administration is preferred over subcutaneous injection, and total cost of medication would be lower. This would be particularly interesting for the future in all "freeze all" protocols such as women undergoing ovarian stimulation for fertility preservation, preimplantation genetic screening and oocyte donation programs.